Search results
Promising trial data for Moderna-Merck skin cancer vaccine sends stock rising
Quartz· 2 days agoModerna stock jumped nearly 4% on Tuesday after the the company announced positive data from an...
FDA vaccine advisers vote unanimously in favor of updated Covid-19 shot for fall
CNN.com· 8 hours agoThe US Food and Drug Administration’s committee of independent advisers voted unanimously Wednesday...
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
CNBC· 3 days agoModerna and Merck released more positive three-year data Monday on their experimental vaccine, given...
US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label
Reuters· 5 days ago, opens new tab respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving...
Study shows new cancer vaccine to treat melanoma has 96% survival rate
UNILAD· 2 days agoA new vaccine treatment for skin cancer melanoma has shown extremely promising results in a new...
New COVID-19 vaccine for fall should target JN.1 lineage, not variant, FDA panel
USA TODAY via Yahoo News· 11 hours agoOfficials noted that COVID-19 is rapidly evolving. The goal of the group was to capture the virus’...
Moderna wins FDA approval for RSV vaccine
BioPharma Dive via Yahoo Finance· 6 days agoThe OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Benzinga· 1 day agoOn Monday, Moderna MRNA and Merck & Co MRK also reported durable efficiency of their combined...
US approves Moderna's RSV vaccine for older adults
Medical Xpress· 6 days agoThe US Food and Drug Administration on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults—marking the first time any...
ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine
FierceBiotech· 3 days agoAs Keytruda’s 2028 patent cliff looms large, Merck & Co.’s renewed R&D oncology strategy focuses on...